Get key Q3 2025 insights on Vir Biotechnology’s accelerated hepatitis delta trial milestones, strong financials, and upcoming data catalysts.
Medpage Today on MSN
Investigational Combination Shows Promise in Chronic Hepatitis D
WASHINGTON -- An investigational dual therapy appeared to show antiviral activity in patients with chronic hepatitis D virus (HDV) infection, according to the phase II SOLSTICE trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback